￥ 人民币 $ USD € 欧元
简体中文 English 繁体中文
Menu

News

Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Lumakras Approved in the U.S. to Treat KRAS-G12C Mutant Non-Small Cell Lung Cancer

2025-10-19 11:44:20

Check Details
Lumakras treats non-small cell lung cancer and achieves overall survival of 12.5 months!

2025-10-19 11:44:20

Check Details
Lung cancer targeted drug Dacomitinib significantly prolongs survival of advanced lung cancer

2025-10-19 11:44:20

Check Details
Pfizer’s second-generation EGFR-TKI dacomitinib_Conhule

2025-10-19 11:44:20

Check Details
ALK-positive metastatic non-small cell lung cancer (NSCLC) new targeted drug-lorlatinib

2025-10-19 11:44:20

Check Details
ALK target-targeted drug: clinical data of lorlatinib

2025-10-19 11:44:20

Check Details
What is the efficacy of pozitinib? What are the common side effects?

2025-10-19 11:44:20

Check Details
Five important things to note when storing tepotinib. It is recommended that you save and forward it!

2025-10-19 11:44:20

Check Details
What is the dosage and dosage of tepotinib and its role in patient treatment?

2025-10-19 11:44:20

Check Details
Another country won: Lumakras® was approved in Japan for the treatment of KRAS G12C mutant advanced non-small cell lung cancer

2025-10-19 11:44:20

Check Details
The emerging anti-cancer all-rounder-ramucirumab

2025-10-19 11:44:20

Check Details
Tepotinib hydrochloride tablets have been approved for marketing for the treatment of non-small cell lung cancer!

2025-10-19 11:44:20

Check Details
Category
相关知识